ENZEEVU

Product NDC: 61314-504
11-digit product format: 613140504
Labeler code: 61314
Product ID: 61314-504_6f1d28a8-1c10-40d2-83f0-6a528f807b92
Type: HUMAN PRESCRIPTION DRUG
Nonproprietary name: aflibercept
Dosage form: INJECTION, SOLUTION
Route: INTRAVITREAL
Labeler: Sandoz Inc
Application: BLA761382
Marketing category: BLA
Marketing start: 2026-10-26
Substance: AFLIBERCEPT
Active strength: 2 mg/.05mL
Pharmacologic classes: Vascular Endothelial Growth Factor Inhibitor [EPC], Vascular Endothelial Growth Factor Inhibitors [MoA]
NDC exclude flag: No
Listing certified through: 2027-12-31
Current FDA listing: Yes

NDC auxiliary status#

These records are reproduced from FDA’s unfinished, excluded, and compounder listings. They describe what appeared in the source files; a missing record does not establish a regulatory status. View all current auxiliary records, including entries without an NDC. · View the auxiliary file history.

Current NDC status page 1 of 1 · 1 matching rows.

Dataset, Scope, Product NDC table
Dataset	Scope	Product NDC	Package NDC	Code	Status	Reporting period	Source date
excluded package	package	61314-504	61314-504-94	D	Discontinued by firm		2026-10-28

Adverse event summaries are temporarily unavailable. Other product information remains available.

Ingredient, Strength table
Ingredient	Strength
AFLIBERCEPT	2 mg/.05mL

BLA, Proprietary name, Proper name table
BLA	Proprietary name	Proper name	License type	Status	Latest source
761382	Enzeevu	aflibercept-abzv	351(k) Biosimilar	Rx	2026-09-01

UNII, Preferred term, Registry number table
UNII	Preferred term	Registry number	Matched term
15C2VL427D	AFLIBERCEPT	862111-32-8	AFLIBERCEPT

Package NDC, 11-digit format, Description table
Package NDC	11-digit format	Description	Marketing start	Sample	Exclude flag	Status
61314-504-63	61314050463	1 SYRINGE, GLASS in 1 CARTON (61314-504-63) / .05 mL in 1 SYRINGE, GLASS	2026-10-26	No	No	Current